Crop protection in 2027: protecting margin, releasing cash and buying selectively

The decision for 2027

A practical agenda for crop protection leaders: defend realised margins, release working capital and assess acquisitions against demand that can be verified.

The most useful question for a crop protection board entering 2027 is where the next unit of capital will earn an acceptable return after discounts, credit and inventory risk. A budget built around shipment growth alone can miss the economics that matter. A distributor may accept another delivery without selling more to growers; an attractive gross margin may disappear once retrospective rebates and extended payment terms are recognised.

Dextra's recommendation is to approve a selective growth agenda with a common cash discipline across the existing portfolio and acquisitions. Protect products whose agronomic value supports a defensible price. Release capital from positions that cannot justify their inventory and service requirements. Pursue acquisitions when customer demand and transferable capabilities support the investment case, with sufficient funding left for integration.

What the latest disclosures tell us

Syngenta Group reported a nine-month 2026 EBITDA margin of 18.4%, up 100 basis points, while Group sales fell 5%. These are Group figures, not a measure of the crop protection market. Its Crop Protection commentary identifies pressure on off-patent pricing in Latin America alongside growth in newer, higher-margin products. [1]

FMC's 29 October disclosure describes changes to its North American pricing and rebate model and actions addressing selected higher-priced inventories held by channel customers. These company-specific adjustments should not be interpreted as an industry demand estimate. [2]

Taken together, the disclosures support a management question rather than a single market forecast: how much of each business's reported performance reflects durable customer demand, and how much depends on mix, commercial terms or inventory timing? The analysis that follows is Dextra's proposed decision framework, not a claim that either company's experience applies uniformly across the sector.

Rebuild the commercial picture around realised margin

Start with the price actually retained by product, country and customer. Reconcile invoice revenue with rebates, promotional support, returns, freight and the financing cost of agreed payment terms. Keep those measures distinct from accounting gross margin so that management can see which decisions change product profitability and which absorb cash elsewhere in the business.

Commercial teams should then compare shipments to distributors with evidence of onward sales. Where reliable sell-through data are unavailable, triangulate distributor stock, reorder patterns and a sample of grower demand. Record uncertainty explicitly. A confident volume forecast based solely on orders placed before the season deserves a different level of commitment from one supported by repeat purchases and collections.

Pricing discipline does not mean rejecting every concession. A targeted discount can be sensible if it secures incremental, collectible demand without creating a wider expectation of price protection. An across-the-board reduction may simply revalue stock already in the channel. Make the intended outcome, customer eligibility and maximum exposure explicit before changing terms.

Allocate investment at product and country level

Product categories are too broad to carry the investment decision. An established active ingredient can remain attractive in a particular crop and distribution model. A differentiated product can disappoint if registration costs, technical support or customer acquisition consume the expected premium.

For each material product-country position, test expected demand against contribution, cash tied up, regulatory expenditure and the capacity needed to serve customers. Expand where evidence supports repeat demand and a viable route to market. Repair positions where a specific change in terms, channel coverage or service could restore acceptable economics. Consider a managed exit where the investment required exceeds a credible return.

Exiting too quickly also has costs. A low-contribution product may support a strategically important customer relationship or complete an agronomic programme. Make that dependency visible and price it into the decision. Portfolio simplification should remove economic complexity, not inadvertently weaken the offer that customers value.

Buy capabilities and demand that survive the transaction

In M&A, the central issue is whether the buyer is paying for recurring earnings or for a commercial position that will need to be reset after completion. Reconcile revenue with customer collections and stock movements. Review aged inventory, subsequent credit notes, rebate commitments and customer concentration. Test whether apparently attractive margins depend on terms that the buyer would not maintain.

Treat registrations and supporting data as a separate diligence workstream. Establish which entity holds each relevant right, whether access depends on third parties, what renewals or expenditure are pending and what the proposed transaction would require. Transferability must be assessed for the relevant jurisdiction and transaction structure with specialist advisers; it should never be assumed from a product list.

Model integration alongside the purchase price. Funding inventory, aligning commercial terms and retaining technical or sales personnel can compete for the same capital. A partnership or distribution agreement may provide a more proportionate way to test a market, although it offers less control. The choice should follow the capability gap and the evidence of demand, rather than an acquisition target becoming the strategy itself.

A 90-day management agenda

Days 1–30: establish a shared baseline. The CFO and commercial director should reconcile realised price, contribution, receivables ageing and inventory by the largest product-country exposures. Track the share of revenue covered by the analysis, unresolved rebate balances and the availability of channel stock data. Agree definitions before using the figures to change incentives.

Days 31–60: test the decisions. Country and portfolio leaders should evaluate a limited set of pricing, replenishment and investment changes. Track realised contribution, repeat orders, collections and stock cover through the relevant seasonal cycle. The M&A team should apply the same commercial tests to shortlisted opportunities, with regulatory specialists documenting rights and outstanding obligations.

Days 61–90: commit and assign accountability. The executive committee should approve the positions to expand, repair or exit, supported by named owners and funding requirements. Review operating cash conversion, overdue receivables and inventory ageing alongside margin. Set improvement targets from the verified baseline; do not impose arbitrary percentages across markets with different crop calendars.

Limits and the board resolution

This report uses two public company disclosures, not a comprehensive market study. It does not establish market size, valuation benchmarks or the prospects of a specific target. Demand, weather, exchange rates, financing costs and registration requirements need to be tested for each opportunity. Downside cases should include delayed collections and slower inventory movement, with a pre-agreed point at which management reduces commitments.

The board should approve a 90-day allocation review and require each material 2027 investment or acquisition proposal to show its expected contribution, working-capital requirement and downside funding need. That creates a practical basis for growth which the business can finance and management can explain.

Sources

[1] Syngenta Group — nine-month 2026 results. Reporting period: first nine months of 2026. Accessed 6 November 2026.

[2] FMC Corporation — third-quarter 2026 results and revised fourth-quarter outlook. Published 29 October 2026; accessed 6 November 2026.